Platshon Scott 4
4 · Zymeworks Inc. · Filed Apr 10, 2026
Research Summary
AI-generated summary of this filing
Zymeworks (ZYME) EVP Platshon Scott Receives Equity Awards
What Happened
Platshon Scott, EVP and Chief Business Officer of Zymeworks Inc. (ZYME), received three equity awards (derivative grants) on April 9, 2026 totaling 193,000 units: 70,000; 47,000; and 76,000. Each grant is reported at $0.00 per unit (standard for compensatory awards). These are awards/grants (transaction code A) rather than purchases or open-market sales — i.e., compensation tied to service and/or performance, not a cash buy or sale.
Key Details
- Transaction date: 2026-04-09; filing date: 2026-04-10 (appears timely).
- Counts and price: 70,000; 47,000; and 76,000 units; $0.00 per unit; total units = 193,000.
- Nature: Reported as derivative awards (could include stock options, restricted stock units (RSUs) and/or performance RSUs (PSUs)); no cash paid.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Notable footnotes in the filing:
- F1: Stock options (if any) vest 25% after one year, then monthly over 36 months.
- F2–F3: RSUs (if any) convert 1-for-1 to common shares on vesting; RSUs vest in four equal annual installments starting on the first anniversary.
- F4–F5: PSUs (if any) are performance-based tied to cumulative total shareholder return (TSR) over a three-year period (performance period ends Jan 12, 2029); target PSUs shown as 38,000 with payout range 50%–200% of target depending on TSR; vesting generally conditioned on continued service with limited exceptions (e.g., certain terminations or change in control).
Context: These awards are compensation intended to align management incentives with shareholder performance and typically vest over time or upon meeting performance targets. They are not the same as an insider buying shares (which some investors view as a bullish signal) or selling shares (which may be routine). For PSUs, final share delivery depends on future performance certification at the end of the performance period.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-04-09+70,000→ 70,000 totalExercise: $27.35Exp: 2036-04-08→ Common Stock (70,000 underlying) - Award
Restricted Stock Unit
[F2][F3]2026-04-09+47,000→ 47,000 total→ Common Stock (47,000 underlying) - Award
Performance Stock Unit
[F4][F5]2026-04-09+76,000→ 76,000 total→ Common Stock (76,000 underlying)
Footnotes (5)
- [F1]Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
- [F2]Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
- [F3]RSUs vest in four equal annual installments beginning on first anniversary of grant date.
- [F4]Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 38,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index.
- [F5](Continued from footnote 4) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).